• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Technology·ORTI-B.ST
Share

Ortivus AB (publ) Stocks

SEK 1.96Last Updated 24.08.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

SEK 17.91M

SEK 1.96
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Ortivus AB (publ) develops and commercializes medical technology solutions and e-health for healthcare industry in Sweden and internationally. The company offers MobiMed Monitor that monitor and shares vital signs and ECG; MobiMed ePR, an electronic patient record system for documentation of treatment and events; MobiMed enRoute, a navigation, case management, and mass casualty management; MobiMed FleetCtrl, a a software application that regular controls, checklists, and documentation tailored for seamless fleet management; MobiMed Life, a heart safe solution. It also provides ambulance services, primary care, and rescue services. The company was incorporated in 1985 and is headquartered in Danderyd, Sweden. Ortivus AB (publ) is a subsidiary of Ponderus Invest AB.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.08.2026 18:05

The U.S. Is Aiming to Isolate Iran Trade-Wise: Which Countries Might Be Affected?

25.08.2026 17:29

Nvidia Could Gain or Lose $280 Billion After Its Earnings Report. What Does Wall Street Expect?

25.08.2026 16:49

Apple is preparing to release a new Mac Mini for the first time in two years — Bloomberg

25.08.2026 16:10

A micro-cap competitor to Meta in the smart glasses market has seen its stock price rise by 60%. What's the reason?

25.08.2026 15:39

Morning in New York: Oil Shrugs Off New Sanctions

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026